Is Cebranopadol legal in Australia?

Not a peptide: a small molecule opioid that also activates the nociceptin peptide receptor. In two head to head healthy volunteer studies it produced less respiratory depression than oxycodone at equal analgesia, and in phase 2 trials it matched or beat morphine and tapentadol. Two phase 3 acute pain trials completed in 2025 and are unpublished. Not approved.

Cebranopadol is in peptide catalogues by mistake, or by association. It is a synthetic small molecule, not a peptide.

Mechanism: 20 ng/mL versus 36 ng/mL); and that its subjective drug liking in recreational opioid users is lower than hydromorphone at doses up to 400 mcg. Its analgesic effect site equilibration is slow, around 8 hours in the 2017 study, which is why phase 2 trials titrated it over weeks.

Regulatory history: Not FDA approved. Two phase 3 acute pain trials completed 2024 to 2025 with no posted results; chronic cancer pain phase 3 terminated for low accrual. No application in openFDA as of September 2026.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Cebranopadol at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.